CHIMERIC ANTIGEN RECEPTOR COMPRISING PA63 DOMAIN 4 VARIANT AS EXTRACELLULAR BINDING DOMAIN, AND USE THEREOF

摘要

The present invention relates to a chimeric antigen receptor that optimizes safety for normal cells while maintaining anticancer effectiveness by controlling binding affinity of a chimeric antigen receptor recognizing an anthrax toxin receptor (ANTXR) antigen and binding thereto, and the present invention relates to: a ligand-based chimeric antigen receptor comprising a PA63 domain 4 variant specifically binding to an ANTXR1 or ANTXR2 cancer antigen; immune cells comprising same; and a use thereof. According to the present invention, the chimeric antigen receptor comprising a PA63 ligand domain 4 variant as an extracellular binding domain may be used to show an excellent anticancer effect for cancer expressing the ARTXR antigen and to optimize safety by controlling binding affinity for the ARTXR antigen such that normal cells are not affected, and, thereby, the chimeric antigen receptor is capable of cancer treatment that is very effective while minimizing side effects of an existing CAR-T immune cell treatment agent.